Overview

An 18-item male tumor genetic panel broadens coverage beyond the core cancer genes, making population selection the central question for any buyer. The test delivers most value when offered to men whose personal or family history suggests an inherited predisposition, rather than as an undirected screen for the general public.

How It Works

Population targeting begins with a pre-test risk assessment: age at first diagnosis in the family, the number of affected relatives, and the presence of syndromic features. The 18-gene panel then interrogates a wider set of loci than the 12-item version, improving the chance of catching a relevant variant in complex families. Mechanically the workflow mirrors other NGS panels, but the population lens determines whether the extra genes justify the incremental cost.

Indications

The panel suits men with a clustered family history of breast, colorectal, prostate or endocrine tumors, those with multiple primary cancers, or patients referred by a clinician after an indicative finding. It is a risk-stratification tool. For B2B channels, the realistic audience is hospitals, boutique labs and occupational-health programmes that already run a counselling pathway, not retail consumers acting alone.

Dosage & Administration

No dosage applies. The relevant specifications are eligibility criteria, sample matrix and report depth. A procurement brief should define the minimum family-history trigger the buyer will accept and the counselling material bundled with each result. Standardise the referral form so that upstream clinicians capture the history needed to interpret the 18-gene output correctly.

Storage & Sourcing

As with any molecular service, sample stability governs accuracy; kits must ship with validated stabilisation and a tracked cold or ambient chain. B2B buyers should confirm the lab's accreditation and its policy on re-testing degraded samples. Population programmes also need a data-handling agreement, because genetic results carry long-term privacy obligations that outlast the individual order.

FAQ

Q: Who is the ideal candidate for the 18-gene panel?

Men with multiple affected relatives, early-onset disease, or more than one primary cancer. The broader gene set helps complex families where a smaller panel might miss the causal variant.

Q: Is this suitable as a general population screen?

Not usually. Unsupervised screening generates uncertain results that require counselling. The panel performs best inside a structured pathway with pre-test selection and post-test interpretation.

Q: How does the 18-item panel differ from the 12-item version?

It covers more loci, raising sensitivity for atypical families at the cost of more variants of uncertain significance to interpret. Buyers should weigh that trade-off against their population's needs.

Q: What support must accompany a population programme?

Genetic counselling resources, a clear report format and a data-retention policy. Without these, a broader panel creates more confusion than clarity.